Kelun-Biotech has reported positive Phase III results for sacituzumab tirumotecan, also known as sac-TMT or SKB264/MK-28...
Novo Nordisk has reported interim Phase III FRONTIER4 extension data for denecimig, also known as Mim8, in people with h...
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administrati...
BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim have announced the launch of a new research t...
Artificial intelligence is rapidly reshaping the way biopharma companies discover, develop, and manufacture medicines. H...
As antibody-drug conjugates (ADCs) transition from a promising therapeutic modality to a cornerstone of precision oncolo...
As antibody-drug conjugates (ADCs), bispecific antibodies and other advanced biologics redefine the global therapeutics ...
The rapid expansion of in vivo gene therapy is reshaping expectations for viral vector manufacturing, placing greater em...
ADCs continue to represent a major growth area for drug developers, with the market projected to reach $69B by 20291. As...
Mubadala Bio has announced the signing of a licencing and supply agreement with Biosidus, a leading biotechnology compan...
Innovent Biologics has dosed the first patient in the Chinese pivotal Phase III TriadicMM-1 trial of IBI3003 for relapse...
During BIO 2026 in San Diego, BioSpectrum Asia spoke with Kurt Imhof, Senior Vice President, Policy & Public Affairs...
As obesity treatment evolves beyond weight loss toward comprehensive cardiometabolic disease management, pharmaceutical ...
Few therapeutic areas have witnessed the level of progress achieved in HIV over the past three decades...
Phanes Therapeutics has completed enrolment in its Phase II study of spevatamig in combination with standard-of-care che...
SystImmune and parent company Sichuan Biokin Pharmaceutical have received regulatory approval in China for iza-bren, als...
As cannabis use expands globally and regulatory frameworks continue to evolve, healthcare systems are increasingly confr...
The search for safer and more effective pain therapies remains one of medicine's most pressing challenges. Despite advan...
The COVID-19 pandemic demonstrated that scientific discovery can move at extraordinary speed, but it also expose...
Artificial intelligence is rapidly transforming biologics discovery, but the industry's focus is shifting from generatin...
Despite decades of advances in oncology, many solid tumours remain difficult to treat effectively without exposing patie...
The RNA revolution is entering a new chapter. While mRNA transformed the industry's perception of nucleic acid therapeut...
Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused o...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
As biotechnology enters an increasingly data-driven era, organisations are rethinking how discovery, clinical developmen...
